Recent changes in Medicare and Medicaid reimbursement have significantly affected the U.S. market for vascular access devices.

The introduction of the “Never Events” policy means that infections acquired during hospitalization will no longer receive reimbursement. This change has encouraged healthcare providers to adopt the use of antimicrobial devices, especially when performing vascular access procedures.

Antimicrobial devices are those that prevent microorganisms from growing. Therefore, the dramatic rise in antimicrobial vascular access devices has greatly contributed to the over $3 billion vascular access industry as of 2009. Vascular access devices that have seen the highest rates of conversion to antimicrobials include central venous catheters (CVCs), dialysis catheters, peripherally inserted central catheters (PICCs) and needleless connectors.

Read all about this interesting market shift in our new article in Healthcare Digital, a global, online news source for healthcare leaders.

Reimbursement Changes to Drive U.S. Market for Vascular Access Devices